Monday, April 19, 2021 4:30:36 AM
1) the patent is decisive
2) Relief is now researching in Germany and is very successful
3) NeuroRx tries to simulate something under ZYESAMI that is actually RLF-100. Therefore, ZYESAMI is unknown to FDA and there is no EUA also.
4) The loss that GEM is currently recording, will be compensated very quickly after Relief receives approval for the "new" RLF-100.
Now the content of Relief's e-mail, dated April 15, 2021, also has a different meaning:
North Bay Resources Announces Composite Assays of 0.53 and 0.44 Troy Ounces per Ton Gold in Trenches B + C at Fran Gold, British Columbia • NBRI • Jun 18, 2024 9:18 AM
VAYK Assembling New Management Team for $64 Billion Domestic Market • VAYK • Jun 18, 2024 9:00 AM
Fifty 1 Labs, Inc Announces Acquisition of Drago Knives, LLC • CAFI • Jun 18, 2024 8:45 AM
Hydromer Announces Attainment of ISO 13485 Certification • HYDI • Jun 17, 2024 9:22 AM
ECGI Holdings Announces LOI to Acquire Pacific Saddlery to Capitalize on $12.72 Billion Market Potential • ECGI • Jun 13, 2024 9:50 AM
Fifty 1 Labs, Inc. Announces Major Strategic Advancements and Shareholder Updates • CAFI • Jun 13, 2024 8:45 AM